
Biogen Inc.
BIIBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 2, 2026 | Guggenheim | Yatin Suneja | $300.00(+18%) | $253.62 | StreetInsider |
| Oct 29, 2026 | RBC Capital | $272.00(+8%) | $251.63 | TheFly | |
| Oct 29, 2026 | Wedbush | $225.00(-11%) | $252.58 | TheFly | |
| Oct 29, 2026 | Argus Research | Jasper Hellweg | $280.00(+11%) | $252.41 | StreetInsider |
| Oct 29, 2026 | UBS | $300.00(+19%) | $252.31 | TheFly | |
| Oct 29, 2026 | Robert W. Baird | $290.00(+19%) | $244.05 | TheFly | |
| Oct 12, 2026 | BMO Capital | $220.00(-6%) | $232.95 | TheFly | |
| Oct 9, 2026 | UBS | $270.00(+21%) | $223.25 | TheFly | |
| Oct 8, 2026 | RBC Capital | $256.00(+16%) | $219.91 | TheFly | |
| Sep 10, 2026 | Stifel Nicolaus | Paul Matteis | $242.00(+13%) | $214.77 | StreetInsider |
| Sep 10, 2026 | HSBC | $175.00(-17%) | $210.73 | TheFly | |
| Sep 3, 2026 | Piper Sandler | $245.00(+10%) | $222.67 | TheFly | |
| Aug 25, 2026 | RBC Capital | $260.00(+19%) | $218.12 | TheFly | |
| Aug 13, 2026 | Wolfe Research | $300.00(+44%) | $208.87 | TheFly | |
| Jul 30, 2026 | Morgan Stanley | Terence Flynn | $231.00(+12%) | $206.50 | TheFly |
| Jul 30, 2026 | H.C. Wainwright | $251.00(+22%) | $205.74 | TheFly | |
| Jul 30, 2026 | RBC Capital | $240.00(+18%) | $204.10 | TheFly | |
| Jul 30, 2026 | UBS | $240.00(+17%) | $204.62 | TheFly | |
| Jul 30, 2026 | Canaccord Genuity | $248.00(+19%) | $209.23 | TheFly | |
| Jul 29, 2026 | Oppenheimer | Jay Olson | $300.00(+43%) | $209.23 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Nov 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 2, 2026 |
| Canaccord Genuity | maintain | Buy | Oct 29, 2026 |
| Needham | maintain | Buy | Oct 29, 2026 |
| Baird | maintain | Outperform | Oct 29, 2026 |
| UBS | maintain | Buy | Oct 29, 2026 |
| Truist Securities | maintain | Buy | Oct 29, 2026 |
| Wedbush | maintain | Neutral | Oct 29, 2026 |
| TD Cowen | maintain | Buy | Oct 29, 2026 |
| Morgan Stanley | maintain | Equal Weight | Oct 29, 2026 |
| RBC Capital | maintain | Outperform | Oct 29, 2026 |
| Argus Research | upgrade | Hold →Buy | Oct 29, 2026 |
| Barclays | maintain | Equal Weight | Oct 28, 2026 |
| B of A Securities | maintain | Neutral | Oct 22, 2026 |
| TD Cowen | maintain | Buy | Oct 21, 2026 |
| Wells Fargo | maintain | Overweight | Oct 20, 2026 |
| JP Morgan | upgrade | Neutral →Overweight | Oct 12, 2026 |
| UBS | maintain | Buy | Oct 9, 2026 |
| RBC Capital | maintain | Outperform | Oct 8, 2026 |
| HSBC | maintain | Reduce | Sep 10, 2026 |
| Piper Sandler | maintain | Overweight | Sep 3, 2026 |
| RBC Capital | maintain | Outperform | Aug 25, 2026 |
| Wolfe Research | upgrade | Peer Perform →Outperform | Aug 13, 2026 |
| Mizuho | maintain | Outperform | Aug 4, 2026 |
| Citigroup | maintain | Neutral | Aug 3, 2026 |
Earnings History
Next report: Feb 5, 2027 · EPS est. $2.85| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $2.62 | $1.99 | $2.80B | $2.63B |
| Jul 29, 2026 | $3.60 | $2.94 | $2.74B | $2.46B |
| Apr 29, 2026 | $3.57 | $3.05 | $2.48B | $2.29B |
| Feb 6, 2026 | $1.99 | $1.63 | $2.28B | $2.20B |
| Oct 30, 2025 | $4.81 | $3.88 | $2.45B | $2.34B |
| Jul 31, 2025 | $5.47 | $3.90 | $2.65B | $2.33B |
| May 1, 2025 | $3.02 | $2.90 | $2.43B | $2.23B |
| Feb 12, 2025 | $3.44 | $3.43 | $2.45B | $2.41B |
News
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement requirements. “Reimbursement decisions from private payers help determine whether a treatment is a real option for families,” said Claire Zlobin, Founder, Life With A Baby. “It's exciting to see that most p.
Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease…
Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.
Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Robin Kramer - Executive VP & CFO Alisha Alaimo - President & Head of North America Conference Call Participants Philip Nadeau - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Di…
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
We have a solid slate of reports today, both of the earnings variety and regarding economic growth.
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.
The biotechnology company said the swing to a loss was primarily due to transaction-related charges.
Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.
Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit
Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts and improving growth portfolio performance. MS franchise and Alzheimer's therapies face patent expiries, competition, and limited efficacy, pressuring BIIB to deliver new blockbuster products. Growth hinges on pipeline readouts, especially litifilimab in SLE, while subQ Leqembi, Spinraza high dose, Syfovre, and Empaveli are key near-term revenue drivers.
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On October 20, 2026, Biogen Inc (BIIB) shares rose 4.1% to a current price of $243.10. This increase comes in the context of a 52-week range that saw lows of $1
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
CWA Asset Management Group LLC raised its holdings in Biogen Inc. (NASDAQ: BIIB) by 11.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,412 shares of the biotechnology company's stock after acquiring an additional 4,285 shares during
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.